

## Media Release

Zug, 31 January 2014

### **HBM Healthcare Investments Quarterly Report December 2013 2013**

During the quarter just ended, the Company's consolidated profit rose by CHF 70 million, to reach a total of CHF 243 million as of the first nine months of the current financial year. Net asset value (NAV) per share also increased over the past three months, by 10 percent to CHF 95.50, whilst the share price advanced by 2 percent to close at CHF 66.25. Including the par value repayment of CHF 1.50 per share, the NAV gained 65 percent in the calendar year 2013, the share price rose by 46 percent during the same period.

The market valuation of the largest holding, Basilea Pharmaceutica, soared by a further 35 percent during the quarter under review, fuelled by positive data from the phase-III study of the company's Isavuconazole antifungal compound, and European market approval for its Ceftobiprole antibiotic. The Basilea holding contributed CHF 44.4 million to the results.

The investment in Pacira Pharmaceuticals also continued to perform well. Revenues from the long-acting analgesic Exparel™ came to USD 30.5 million in the fourth quarter, taking the total for calendar 2013 year to USD 76.2 million – compared with USD 14.6 million in 2012. Pacira's market capitalisation rose by 20 percent to just under USD 2 billion during the reporting period, and contributed around CHF 13.2 million to profits for the quarter.

#### **Investment activity**

In the private companies segment of the portfolio, HBM Healthcare Investments invested a total of CHF 3.8 million in follow-on financing for existing portfolio companies. The ownership interest in Westmed was raised to over 20 percent with an additional investment of USD 1.5 million. Furthermore, smaller investments were made in Delenex (CHF 1.3 million), Tensys (USD 0.7 million) and Nabriva (EUR 0.3 million).

From the portfolio of public companies, further profits from Basilea Pharmaceutica were taken, and the holding in the company was reduced to just under 12 percent. Meanwhile, the holdings in

# NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

## HBM Healthcare Investments

Swedish Orphan Biovitrum and SkyePharma were extended to some degree. HBM Healthcare Investments also invested some of its disposable funds in other, attractively valued companies which offer considerable value creation potential.

### Outlook

The new year got off to a pleasing start for HBM Healthcare Investments. More positive results from a number of portfolio companies are expected. In view of the significant share of the portfolio that is held in public companies, HBM Healthcare Investments is increasingly exposed to movements on the equity markets as a whole. The Company will maintain the shareholder-friendly distribution programme over the next twelve months.

The online version of the Quarterly Report as at 31 December 2013 is available on the HBM Healthcare Investments website [www.hbmhealthcare.com](http://www.hbmhealthcare.com).

For further information, please contact Dr. Andreas Wicki, tel.: +41 41 768 11 08, [andreas.wicki@hbmhealthcare.com](mailto:andreas.wicki@hbmhealthcare.com)

### Information on HBM Healthcare Investments Ltd

HBM Healthcare Investments actively invests in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. The company holds and manages an international portfolio of some twenty five promising companies. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes HBM Healthcare Investments an interesting alternative to investing in big pharma and biotech companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

### Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or

### HBM Healthcare Investments Ltd

Bundesplatz 1 CH-6300 Zug | Tel: +41 41 768 11 08 | Fax: +41 41 768 11 09 | [info@hbmhealthcare.com](mailto:info@hbmhealthcare.com)  
[www.hbmhealthcare.com](http://www.hbmhealthcare.com)

# NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

**HBM** Healthcare  
Investments

invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

**HBM Healthcare Investments Ltd**

Bundesplatz 1 CH-6300 Zug | Tel: +41 41 768 11 08 | Fax: +41 41 768 11 09 | [info@hbmhealthcare.com](mailto:info@hbmhealthcare.com)  
[www.hbmhealthcare.com](http://www.hbmhealthcare.com)